Epithelial ovarian cancer: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
| Line 79: | Line 79: | ||
| | | | ||
|- | |- | ||
|PIP3/Akt | |||
| | | | ||
| | |||
|- | |||
|PTEN | |||
| | |||
| | |||
|- | |||
|p53 | |||
| | |||
| | |||
|- | |||
|BRCA1 | |||
| | |||
| | |||
|- | |||
|BRCA2 | |||
| | |||
| | |||
|- | |||
|MLH1/MSH2 | |||
| | | | ||
| | | | ||
|- | |- | ||
|Fas ligand | |||
| | |||
| | | | ||
|- | |||
|HLA-G | |||
| | | | ||
| | | | ||
|- | |- | ||
|hTERT | |||
| | | | ||
| | |||
|- | |||
|VEGF/VEGFR | |||
| | | | ||
| | | | ||
|- | |- | ||
|IL-8 | |||
| | |||
| | | | ||
|- | |||
|EphA2 | |||
| | | | ||
| | | | ||
|- | |- | ||
|MMPs | |||
| | |||
| | | | ||
|- | |||
|αvβ3 | |||
| | | | ||
| | | | ||
|- | |- | ||
|FAK | |||
| | | | ||
| | |||
|- | |||
|E-cadherin | |||
| | | | ||
| | | | ||
Revision as of 14:58, 26 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]
| Possible genetic alteration in epithelial ovarian cancers | ||
|---|---|---|
| Protein | Normal function | Result of mutation |
| EGFR(HER-1) | ||
| HER-2 | ||
| Src | ||
| CSF-1/fms | ||
| ILGF/ILGFR | ||
| k-ras | ||
| b-raf | ||
| TGF-β | ||
| myc | ||
| Cyclin D/Cdk4/6 | ||
| Cyclin E/Cdk2 | ||
| Cyclin B/Cdk1 | ||
| p16 | ||
| p27 (kip-1) | ||
| p21 (WAF-1) | ||
| NFκB | ||
| NOEY(ARHI) | ||
| PIP3/Akt | ||
| PTEN | ||
| p53 | ||
| BRCA1 | ||
| BRCA2 | ||
| MLH1/MSH2 | ||
| Fas ligand | ||
| HLA-G | ||
| hTERT | ||
| VEGF/VEGFR | ||
| IL-8 | ||
| EphA2 | ||
| MMPs | ||
| αvβ3 | ||
| FAK | ||
| E-cadherin | ||